Thelansis

Knee Osteoarthritis (OA) Market Outlook Thelansis’s “Knee Osteoarthritis (OA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Knee Osteoarthritis (OA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s tra...

Knee Osteoarthritis (OA) Market Outlook Thelansis’s “Knee Osteoarthritis (OA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Knee Osteoarthritis (OA)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Knee Osteoarthritis (OA) Overview Knee osteoarthritis (OA) is a common progressive joint disease that causes pain and disability. It is the most common form of OA, accounting for almost 4/5th of the global burden of the disease. Knee OA increases with age and obesity and is incurable except through knee arthroplasty, an effective treatment at an advanced stage of the disease but is responsible for substantial health costs. ...

 Knee osteoarthritis (OA) is a common progressive joint disease that causes pain and disability. It is the most common form of OA, accounting for almost 4/5th of the global burden of the disease. Knee OA increases with age and obesity and is incurable except through knee arthroplasty, an effective treatment at an advanced stage of the disease but is responsible for substantial health costs. Knee osteoarthritis is characterized by chronic pain and functional disability. Pain results from inflammation and damage to the joint, including thickening of the joint capsule and the formation of osteophytes (bone spurs). A study found that 43.3% of people reported having pain, aching, or stiffness in a knee joint on most days. The prevalence of pain increased with age, from 34.2% in people aged 45 to 54 years to 56.6% in people aged 75 years and older. No drugs currently approved can prevent, stop, or even slow the progression of OA. The available medications that promise to mitigate the pai...

Knee osteoarthritis (OA) is a common progressive multifactorial joint disease characterized by chronic pain and functional disability. Knee OA accounts for almost four-fifths of the burden of OA worldwide and increases with obesity and age. Knee OA is incurable except knee arthroplasty, which is considered an effective treatment at an advanced stage of the disease. However, which is responsible for substantial health costs. Pain results in the affected joint, including thickening of the joint capsule and the formation of osteophytes. Overall, 43.3% reported having pain, aching, or stiffness in a knee joint on most days.15 Reports of pain increased with age (45 to 54 years, 34.2%; 75 years and older, 56.6%). ·        The overall global prevalence of knee osteoarthritis (OA) was 16.0% in individuals aged 15 and over and was 23.2% in individuals aged 40 and over. ·        Presently there are no drugs approved that can prevent, sto...

Knee osteoarthritis (OA) is a common progressive multifactorial joint disease characterised by chronic pain and functional disability. Knee OA accounts for almost four-fifths of the burden of OA worldwide and increases with obesity and age. Knee OA is incurable except knee arthroplasty, which is considered an effective treatment at an advanced stage of the disease; but is responsible for substantial health costs. Pain results in the affected joint, including thickening of the joint capsule and the formation of osteophytes. Overall, 43.3% reported having pain, aching, or stiffness in a knee joint on most days.15 Reports of pain increased with age (45 to 54 years, 34.2%; 75 years and older, 56.6%). ·        The overall global prevalence of knee OA was 16.0% in individuals aged 15 and over and was 23.2% in individuals aged 40 and over. ·        Presently, there are no drugs approved that can prevent, stop, or even restrain the pro...